UBS Maintains a 'Buy' on CVS Caremark (CVS); Raising FY12/13 EPS Estimates

UBS maintains a 'Buy' on CVS Caremark (NYSE: CVS) price target raised $1 to $49.

UBS analyst says, "Following CVS’ 4Q11 conf call, we are raising our 2012 EPS estimate from $3.20 to $3.26 to now reflect some of the potential upside related to the WAG/ESRX dispute. Our PBM projections are essentially unchanged, while all the upside is captured in the retail segment. The key is to decipher timing of resolution between Walgreen (NYSE: WAG) / Express Scripps (Nasdaq: ESRX)." (UBS raises FY13 from $3.68 to $3.70)

For an analyst ratings summary and ratings history on CVS Caremark click here. For more ratings news on CVS Caremark click here.

Shares of CVS Caremark closed at $43.57 yesterday, with a 52 week range of $31.30-$44.09.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Needham & Company Reiterates a 'Buy' on NetApp (NTAP); Solid 4Q Overshadowed by Conservative 1Q
• Nomura Securities Raises PT and Estimates on PetSmart (PETM) After Good Q1
• Barclays Maintains an 'Equalweight' on J. C. Penney (JCP); Slashing PT on Disappointing Results

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter